# Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder

> **NCT00191880** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 100 (—)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** atomoxetine

## Key facts

- **NCT ID:** NCT00191880
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 100 (—)
- **Last updated:** 2006-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191880, "Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00191880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*